Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Economic Burden of Cardiovascular Disease in the United States.

The American journal of cardiology·2026
Same author

Baseline Dementia Prevalence and Subtypes in Older Adults Hospitalized With Acute Coronary Syndrome: A Multicenter Study From a Large Integrated Health Care Delivery System.

The Permanente journal·2026
Same author

The Impact of Cognitive Impairment on Cardiovascular Disease.

Journal of the American College of Cardiology·2025
Same author

Frailty and PCI Outcomes: Turning Registry Insights Into Health System Action.

Journal of the American College of Cardiology·2025
Same author

Effect of Uptitration of Recommended Heart Failure Medications on Restricted Mean Survival Time in STRONG-HF.

JACC. Heart failure·2025
Same author

The Multidisciplinary Heart Team in Cardiovascular Medicine: Current Role and Future Challenges.

JACC. Advances·2024
Same journal

Health Care Utilization and Pediatric Appendicitis: Insights From an Integrated Health System.

The Permanente journal·2026
Same journal

Colorectal Cancer Screening Materials for Tribal Communities in the Great Plains and Washington State: Application of Boot Camp Translation.

The Permanente journal·2026
Same journal

Mild Thrombocytopenia at Admission to Labor and Delivery: Implications for Postpartum Hemorrhage.

The Permanente journal·2026
Same journal

Introduction to Issue 30:2 by the Editor-in-Chief.

The Permanente journal·2026
Same journal

Introduction to the Special Section on Improving Health Care Access.

The Permanente journal·2026
Same journal

Continued Reflections on the 30th Anniversary of <i>The Permanente Journal</i>.

The Permanente journal·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Thiazolidinediones: a 2010 perspective.

Ashok Krishnaswami, Shalini Ravi-Kumar, John M Lewis

    The Permanente Journal
    |September 17, 2010
    PubMed
    Summary
    This summary is machine-generated.

    Thiazolidinediones (TZD) are a class of diabetes medications. While not proven to reduce mortality, this review aids clinicians in assessing TZD benefits and risks for cardiovascular outcomes.

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    An In Ovo Model for Testing Insulin-mimetic Compounds
    06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Cardiology trials often use mortality as an endpoint, but surrogate endpoints are preferred when available.
    • Current diabetes mellitus treatments lack proven mortality benefits in clinical trials.
    • The United Kingdom Prospective Diabetic Study hinted at metformin's potential mortality reduction.

    Purpose of the Study:

    • To review thiazolidinediones (TZDs) as a treatment for diabetes mellitus.
    • To assess the cardiovascular benefits and risks associated with TZD use.
    • To guide clinicians in prescribing TZDs for optimal patient outcomes.

    Main Methods:

    • Review of existing clinical trial data and pharmacological studies on thiazolidinediones (TZDs).
    • Analysis of the role of peroxisome proliferator-activated receptors (PPARs) in TZD action.
    • Evaluation of glycemic control and cardiovascular outcomes in patients using TZDs.

    Main Results:

    • Thiazolidinediones (TZDs) are PPAR agents offering potential for diabetes treatment.
    • No current diabetes medications, including TZDs, have demonstrated a definitive mortality benefit.
    • Increasing cardiovascular complications in diabetes necessitate medications with improved cardiovascular outcomes.

    Conclusions:

    • Clinicians must carefully weigh the benefits and risks of thiazolidinediones (TZDs).
    • Further research is needed to confirm TZD efficacy in improving cardiovascular outcomes.
    • The goal is to achieve safe glycemic control alongside enhanced cardiovascular health in diabetic patients.